Annals of Hematology

, Volume 71, Issue 4, pp 195–198 | Cite as

Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro

  • D. A. Tsakiris
  • M. -L. Yasikoff
  • F. Wolf
  • G. A. Marbet
Original Article


Anticardiolipin antibodies (aCL) or lupus anticoagulants (LA) have been found to exert an inhibitory action upon the activation and function of protein C, a natural coagulation inhibitor. Recently an in vitro phenomenon called resistance to activated protein C (APC resistance) has been described as the most frequent cause of hereditary thrombophilia. In order to see whether a positive association of APC resistance with aCL exists we examined plasma of 162 consecutive outpatients referred for thrombophilia screening. Further, the IgG fraction was isolated from plasma of two aCL-positive and LA-negative patients and of two aCL-negative healthy subjects by means of protein A affinity chromatography. Each of these isolates was mixed with normal plasma, and the APC resistance was assayed; 25/162 (15.4%) patients had confirmed abnormal APC resistance. Only 1/25 (4.0%) APC resistance-positive patients and 11/137 (8.0%) APC resistance-negative patients had positive IgG- and/or IgM-aCL (p=0.5, nonsignificant). In the in vitro test system the APC resistance ratio remained unaffected after addition of normal IgG or aCL-IgG fraction in the tested normal plasma and did not deviate from the range of buffer controls. These data do not suggest any association of aCL with abnormal APC resistance. aCL-IgG fractions from aCL-positive and LA-negative plasmas do not interfere with the APC resistance test system in vitro in low concentration.

Key words

Anticardiolipin antibodies Lupus anticoagulants APC resistance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bertina RM, Koelman PC, Koster T, et al (1994) Mutation in blood coagulation factor V, associated with resistance to activated protein C. Nature 369:64–67PubMedGoogle Scholar
  2. 2.
    Bokarewa MI, Blombäck M, Egberg N, Roséen S (1994) A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinolysis 5:37–41PubMedGoogle Scholar
  3. 3.
    Borrell M, Sal N, de Carsellarnau C, Lopez S, Fontcuberta J (1992) Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 68:268–272PubMedGoogle Scholar
  4. 4.
    Cadroy Y, Sié P, Boneu B (1994) Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 83:2008–2009PubMedGoogle Scholar
  5. 5.
    Cariou R, Tobelem G, Bellucci S, et al (1988) Effect of lupus anticoagulant on antithrombotic properties of endothelial cells. Inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 60:54–58PubMedGoogle Scholar
  6. 6.
    Carreras LO, Vermylen J (1991) Antiphospholipid antibodies and impairment of prostacyclin synthesis by endothelium. In: Harris EN, Exner T, Hughes GRV, Asherson R (eds) Phospholipid binding antibodies. CRC Press, Boca Raton, pp 231–245Google Scholar
  7. 7.
    Dahlbäck B (1995) Inherited thrombophilia: resistance to activated protein C a pathogenic factor of venous thromboembolism. Blood 85:607–614PubMedGoogle Scholar
  8. 8.
    Dahlbäck B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90:1004–1008PubMedGoogle Scholar
  9. 9.
    De Groot PhG, Derksen RHWM (1994) Protein C pathway, antiphospholipid antibodies and thrombosis. Lupus 3:229–233PubMedGoogle Scholar
  10. 10.
    De Groot PhG, Oosting JD, Derksen RHWM (1993) Antiphospholipid antibodies: specificity and pathophysiology. Bailleres Clin Haematol 6:691–709Google Scholar
  11. 11.
    Exner T (1993) Some recent developments with lupus anticoagulants. Blood Coagul Fibrinolysis 5:281–289Google Scholar
  12. 12.
    Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave JP (1986) An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipids on purified endothelial thrombomodulin activity. A mechanism for thrombosis Thromb Haemost 55:309–313PubMedGoogle Scholar
  13. 13.
    Galli M, Bevers EM (1994) Inhibition of phospholipid-dependent coagulation reactions by “antiphospholipid antibodies”: possible modes of action Lupus. 3:223–228PubMedGoogle Scholar
  14. 14.
    Galli M, Comfurius P, Barbui T, et al (1992) Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 68:297–300PubMedGoogle Scholar
  15. 15.
    Gschwandner ME, Lechner K, Pabinger I (1995) Erroneously low APC ratio in patients with lupus anticoagulant. Ann Hematol 70:169–170PubMedGoogle Scholar
  16. 16.
    Halbmayer WM, Haushofer A, Schön R, Fischer M (1994) Influence of lupus anticoagulant on a commercially available kit for APC resistance. Thromb Haemost 72:645–646PubMedGoogle Scholar
  17. 17.
    Harris EN (1990) Antiphospholipid antibodies. Br J Haematol 74:1–9Google Scholar
  18. 18.
    Koster T, Rosendaal RS, de Tonde H, Briet E, Bandenbroucke JP, Bertina RM (1993) Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503–1506PubMedGoogle Scholar
  19. 19.
    Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport SI (1995) Use of a generally applicable tissue factor dependent factor Va assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 85:1704–1711PubMedGoogle Scholar
  20. 20.
    Love PE, Santoro SA (1990) Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 112:682–698PubMedGoogle Scholar
  21. 21.
    Malia RG, Kitchen S, Greaves M, Preston FE (1990) Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 76:101–107PubMedGoogle Scholar
  22. 22.
    Marciniak E, Romond EH (1989) Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 74:2426–2432PubMedGoogle Scholar
  23. 23.
    Oosting JD, Derksen RHWM, Bobbing WG, Hackeng TM, Bouma BM, de Groot PhG (1993) Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism? Blood 81:2618–2625PubMedGoogle Scholar
  24. 24.
    Oosting JD, Preissner KT, Derksen RHWM, de Groot PhG (1993) Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 85:761–768PubMedGoogle Scholar
  25. 25.
    Pötzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Müller-Berghaus G (1995) Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 125:56–65PubMedGoogle Scholar
  26. 26.
    Svensson PJ, Dahlbäck B (1994) Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517–522PubMedGoogle Scholar
  27. 27.
    Tobelem G (1990) Les anticorps antiphospholipides: spécificité et méchanismes d'action. Ann Med Interne (Paris) 141:257–260Google Scholar
  28. 28.
    Triplett DA, Brandt J (1989) Laboratory identification of the lupus anticoagulant. Br J Haematol 73:139–142PubMedGoogle Scholar
  29. 29.
    Tsakiris DA, Marbet GA, Makris PE, Settas L, Duckert F (1989) Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb Haemost 61:175–177PubMedGoogle Scholar
  30. 30.
    Tsakiris DA, Settas L, Makris PE, Marbet GA (1990) Lupus anticoagulant, antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-thrombomodulin. J Rheumatol 17:785–789PubMedGoogle Scholar
  31. 31.
    Zoller B, Dahlbäck B (1994) Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343:1536–1538PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • D. A. Tsakiris
    • 1
  • M. -L. Yasikoff
    • 1
  • F. Wolf
    • 1
  • G. A. Marbet
    • 1
  1. 1.Hemostasis Laboratory DCLUniversity Hospital BaselBaselSwitzerland

Personalised recommendations